Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Escudier

Showing results (51-60 of 362) with videos related to

Pageof 37
Sort By:
Expert Review of Anticancer Therapy|April 25, 2015
Axitinib in metastatic renal cell carcinomaLaurence Albiges, Marco Gizzi, Edith Carton, et al.
The Oncologist|August 31, 2018
The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell CarcinomaEmiliano Calvo, Camillio Porta, Viktor Grünwald, et al.
Lancet (London, England)|March 10, 2009
Renal cell carcinomaBrian I Rini, Steven C Campbell, Bernard Escudier
Clinical Genitourinary Cancer|March 3, 2012
Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapyPhilip J Saylor, Bernard Escudier, M Dror Michaelson
Hematology/Oncology Clinics of North America|July 19, 2011
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinomaLaurence Albiges, Mohamed Salem, Brian Rini, et al.
Drugs|July 1, 2020
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell CarcinomaLaure Hirsch, Ronan Flippot, Bernard Escudier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 5, 2002
[Metastatic kidney cancer: new therapeutic approaches]Sylvie Negrier, Arnaud Mejean, Stéphane Oudard, et al.
BJU International|October 31, 2012
Tumour burden is an independent prognostic factor in metastatic renal cell carcinomaRoberto Iacovelli, Emilie Lanoy, Laurence Albiges, et al.
American Journal of Clinical Oncology|June 7, 2007
Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancerRonald Bukowski, David Cella, Kathleen Gondek, et al.
The Lancet. Oncology|August 8, 2015
Relapse models for clear cell renal carcinoma - Authors' replyBrian Rini, Audrey Goddard, Dejan Knezevic, et al.
Pageof 37

Showing results (51-60 of 362) with videos related to

Sort By:
Pageof 37
Expert Review of Anticancer Therapy|April 25, 2015
Axitinib in metastatic renal cell carcinomaLaurence Albiges, Marco Gizzi, Edith Carton, et al.
The Oncologist|August 31, 2018
The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell CarcinomaEmiliano Calvo, Camillio Porta, Viktor Grünwald, et al.
Lancet (London, England)|March 10, 2009
Renal cell carcinomaBrian I Rini, Steven C Campbell, Bernard Escudier
Clinical Genitourinary Cancer|March 3, 2012
Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapyPhilip J Saylor, Bernard Escudier, M Dror Michaelson
Hematology/Oncology Clinics of North America|July 19, 2011
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinomaLaurence Albiges, Mohamed Salem, Brian Rini, et al.
Drugs|July 1, 2020
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell CarcinomaLaure Hirsch, Ronan Flippot, Bernard Escudier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 5, 2002
[Metastatic kidney cancer: new therapeutic approaches]Sylvie Negrier, Arnaud Mejean, Stéphane Oudard, et al.
BJU International|October 31, 2012
Tumour burden is an independent prognostic factor in metastatic renal cell carcinomaRoberto Iacovelli, Emilie Lanoy, Laurence Albiges, et al.
American Journal of Clinical Oncology|June 7, 2007
Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancerRonald Bukowski, David Cella, Kathleen Gondek, et al.
The Lancet. Oncology|August 8, 2015
Relapse models for clear cell renal carcinoma - Authors' replyBrian Rini, Audrey Goddard, Dejan Knezevic, et al.
Pageof 37